Myasthenia Gravis Related Research Tools

Myasthenia gravis (MG) is an autoimmune disease caused by antibodies against the acetylcholine receptor (AChR), muscle-specific kinase (MuSK) or other AChR-related proteins in the postsynaptic muscle membrane. Localized or general muscle weakness is the predominant symptom and is induced by the antibodies. Traditionally, most patients with MG require induction therapy with high doses of corticosteroids and maintenance with an immunosuppressant. Nowadays, biologics are emerging as important therapeutic tools that provide better corticosteroid-sparing effects than standard treatments and can even induce remission.

As shown in Fig.1, immunotherapeutics that target different elements in these pathways are shown in yellow boxes. The AChR is presented to CD4+ T cells by antigen-presenting cells (APCs) via co-stimulatory molecules. Downstream upregulation of cytokines stimulates B cells to produce anti-AChR antibodies that lead to the destruction of AChRs by fixing complement at the neuromuscular endplate region. Levels of regulatory T (Treg) and T helper (TH) 17 cells and cytokines are increased in patients with MG, thereby causing the immune imbalance.

Several biologic agents have shown promising effects in studies of their efficacy in MG to date. The success suggests that the emergence of new molecular targets could bring a revolution in the treatment of MG. Creative Biolabs has screened the most popular targets and provides high-quality products as well as customized services for our clients. For more services and products, please contact us.

CD19	CD20	CD80	CD86
IL-2	IL-4	IL-6	IL-17
IL-22	JAK1	JAK2	JAK3
AchR	PD-1	PD-L1	CTLA4
C5	C3	TNF	B cell trophic factor (BAFF)

For Research Use Only. Not For Clinical Use.

Target

NRG3

GEMIN8

Insulin Receptor Beta

CacyBP

FABP3

CRMP5

PITX3

CDK3

OPA1

Cathepsin D

LC3B

NSE

Monoamine Oxidase B

ALS2CR1

NF-L

Plexin A2

POU5F1

ATOH1

GFAP

PGP9.5

ALDH3A2

NTRK2

Spastin

ABCA4 Rim Protein

CDK2

CRBN

Synaptogyrin

Neurofilament L

HIP1

CD11b

Alpha Synuclein

Glypican 1